All In Biotech

NDA 216340 · Bristol

Krazati

Adagrasib · Oral

NovelBreakthrough therapyAccelerated approvalOrphan

CDER novel approval, Dec 12, 2022: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 12, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

38

5 Phase 3, 10 recruiting

FAERS reports

1,134

878 serious, 349 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

KRAZATI, as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial. KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1 ) *This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in confirmatory trials.

Mechanism: Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state that prevents downstream signaling without affecting wild-type KRAS protein. Adagrasib inhibited tumor cell growth and viability in cells harboring KRAS G12C mutations and resulted in tumor regression in KRAS G12C-mutated tumor xenograft models with minimal off-target activity.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 21, 2024 Supplement 5 · Efficacy · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
  • Dec 12, 2022 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • KRAZATI · ADAGRASIB 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Adagrasib" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death306
  • diarrhoea133
  • hospitalisation116
  • nausea106
  • off label use95
  • vomiting90
  • asthenia72
  • fatigue63
  • decreased appetite48
  • dehydration43
  • dyspnoea40
  • acute kidney injury36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20226
2023365
2024385
2025201
2026176

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Krazati (Adagrasib)

2024 spending

$69.7M

Beneficiaries

1,042

3,873 claims

Per beneficiary

$66,903

$119.70 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$22,747,939
2024$69,712,635

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.